| COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study LYW Lee, JB Cazier, T Starkey, SEW Briggs, R Arnold, V Bisht, S Booth, ... The Lancet Oncology, 2020 | 621 | 2020 |
| DNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer DN Church, SEW Briggs, C Palles, E Domingo, SJ Kearsey, JM Grimes, ... Human molecular genetics 22 (14), 2820-2828, 2013 | 391 | 2013 |
| Germline and somatic polymerase ϵ and δ mutations define a new class of hypermutated colorectal and endometrial cancers S Briggs, I Tomlinson The Journal of pathology 230 (2), 148-153, 2013 | 295 | 2013 |
| Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study E Domingo, L Freeman-Mills, E Rayner, M Glaire, S Briggs, L Vermeulen, ... The lancet Gastroenterology & hepatology 1 (3), 207-216, 2016 | 283 | 2016 |
| Association analyses identify 31 new risk loci for colorectal cancer susceptibility PJ Law, M Timofeeva, C Fernandez-Rozadilla, P Broderick, J Studd, ... Nature Communications, 2019 | 207 | 2019 |
| Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett’s esophagus C Palles, L Chegwidden, X Li, JM Findlay, G Farnham, FC Giner, ... Gastroenterology 148 (2), 367-378, 2015 | 119 | 2015 |
| Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries C Fernandez-Rozadilla, M Timofeeva, Z Chen, P Law, M Thomas, ... Nature genetics 55 (1), 89-99, 2023 | 65 | 2023 |
| Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis using UK Biobank data: population based cohort study SEW Briggs, P Law, JE East, S Wordsworth, M Dunlop, R Houlston, ... bmj 379, 2022 | 23 | 2022 |
| UK Coronavirus Cancer Monitoring Project Team. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a … LYW Lee, JB Cazier, T Starkey, SEW Briggs, R Arnold, V Bisht, S Booth, ... Lancet Oncol 21 (10), 1309-1316, 2020 | 15 | 2020 |
| Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer V Gray, S Briggs, C Palles, E Jaeger, T Iveson, R Kerr, MP Saunders, ... JNCI: Journal of the National Cancer Institute 111 (8), 828-836, 2019 | 12 | 2019 |
| Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities S Briggs, I Slade Current Genetic Medicine Reports 7 (2), 63-74, 2019 | 9 | 2019 |
| Cancer and climate change: the environmental impact of cancer care S Briggs, J Cavet, C Lamb, S Lightowlers The Lancet Oncology 22 (2), e38, 2021 | 7 | 2021 |
| Focusing attention on physicians’ climate-related duties may risk missing the bigger picture: towards a systems approach to health and climate G Samuel, S Briggs, F Hardcastle, K Lyle, E Parker, AM Lucassen Journal of Medical Ethics, 2024 | 1 | 2024 |
| Building climate resilient and low carbon health systems S Briggs bmj 383, 2023 | 1 | 2023 |
| Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes Z Chen, X Guo, R Tao, JR Huyghe, PJ Law, C Fernandez-Rozadilla, ... Nature Communications 15 (1), 3557, 2024 | | 2024 |
| A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity. C Palles, M Lucas, K Watts, S Galavotti, IS Chin, C Campbell, SEW Briggs, ... Journal of Clinical Oncology 41 (16_suppl), 3028-3028, 2023 | | 2023 |
| Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis: a cohort study in UK Biobank SEW Briggs, P Law, JE East, S Wordsworth, M Dunlop, R Houlston, ... medRxiv, 2021.09. 22.21263962, 2022 | | 2022 |
| Clinical Insights: Antiangiogenesis in Cancer Therapy B Basu, S Biswas, S Pacey, SJ Welsh, T Janowitz, P Corrie, ... Future Medicine, 2014 | | 2014 |
| Editorial on polygenic risk scores-colloquium held at the Centre for Personalised Medicine, Oxford P Dixon, S Briggs, A Lucassen Cambridge Prisms: Precision Medicine, 1-7, 0 | | |
| Antiangiogenesis: focus on colorectal cancer S Briggs, R Midgley Antiangiogenesis in Cancer Therapy, 69, 0 | | |
